EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

J Thorac Oncol. 2021 Nov;16(11):1788-1792. doi: 10.1016/j.jtho.2021.06.004.

Authors

Sara Moore¹, Paul Wheatley-Price²

Affiliations

¹ Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
² Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address: pwheatleyprice@toh.ca.

PMID: 34716002
DOI: 10.1016/j.jtho.2021.06.004

No abstract available

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Combined Modality Therapy
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors